Outlook Therapeutics: Funding, Investors & Team (Sep 2026)
OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.
Outlook Therapeutics has raised $30.0M across 2 funding rounds on record, the most recent an undisclosed round of $5.0M announced in Apr 2026.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Outlook Therapeutics Company Profile and Key Stats
Latest funding round on record: Apr 2026.
Outlook Therapeutics Funding Rounds
Outlook Therapeutics raised $25.0M in an undisclosed round announced in Dec 2022.
3.3 years later, an undisclosed round of $5.0M was announced in Apr 2026.
Outlook Therapeutics Founders and Leadership Team
Contact details for the Outlook Therapeutics team: 1 of 2 have an email address on file.
Start 14-day free trial →Outlook Therapeutics Funding Compared to Other Biotechnology Startups
Outlook Therapeutics' latest round of $5.0M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Outlook Therapeutics in Biotechnology and Cranbury
Companies Similar to Outlook Therapeutics
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Outlook Therapeutics Funding FAQs
What does Outlook Therapeutics do?
OVERVIEW Oncobiologics is a clinical stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics. Our current focus is on technically challenging and commercially attractive monoclonal antibodies (mAbs), in the disease areas of immunology and oncology. Our strategy is to cost-effectively develop these biosimilars on an accelerated timeline, which is fundamental to our success and we believe positions us to be a leading biosimilar company. We have leveraged our team’s biopharmaceutical expertise to establish fully integrated in-house development and manufacturing capabilities, which we refer to as our BioSymphony™ Platform. Oncobiologics’ platform addresses the numerous complex technical and regulatory challenges in developing and commercializing mAb biosimilars and was designed to provide significant pricing flexibility. PIPELINE Oncobiologics is currently developing a portfolio of eight commercially attractive mAb biosimilars. The company’s most advanced assets, ONS-3010 (a biosimilar of Humira®) and ONS-1045 (a biosimilar of Avastin®) have both successfully completed Phase I trials. We have initiated Phase 3 preparatory activities for ONS-3010 and ONS-1045.` STRATEGY Oncobiologics utilizes its BioSymphony Platform to develop, manufacture and commercialize technically challenging, cost-effective biosimilars on an accelerated timeline and to offer contract development and manufacturing services to development stage biologics companies.
How much funding has Outlook Therapeutics raised?
Outlook Therapeutics has raised $30.0M across 2 rounds on record. The most recent is an undisclosed round of $5.0M announced in Apr 2026.
When did Outlook Therapeutics last raise funding?
Outlook Therapeutics' most recent funding round on record is an undisclosed round of $5.0M, announced in Apr 2026.
Who founded Outlook Therapeutics?
FundedIQ lists Bob Jahr (Founder) at Outlook Therapeutics.
Who is the CEO of Outlook Therapeutics?
C Russell Trenary is listed as CEO at Outlook Therapeutics.
Where is Outlook Therapeutics headquartered?
Outlook Therapeutics is based in Cranbury, New Jersey, United States.
How many employees does Outlook Therapeutics have?
Outlook Therapeutics is in the 101-250 employee band.
How does Outlook Therapeutics' funding compare to other Biotechnology startups?
Outlook Therapeutics' latest round of $5.0M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Outlook Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Outlook Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.